ArticleScientific reports2025
An inactivated bivalent vaccine effectively protects Carassius auratus against Aeromonas caviae and Aeromonas veronii.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral Vaccination withVaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Aeromonas veronii (A. veronii) and Aeromonas caviae (A. caviae) are important pathogens that affect various fish species. In this study, a whole-cell bivalent vaccine against A. veronii and A. caviae was developed to assess the immune response of Carassius auratus(C. auratus). Initially, the inactivation temperature and formalin concentration were investigated. After confirming safety, three different vaccine concentrations were administered via injection, and a random selection of C. auratus was subjected to tail vein blood collection. The serum levels of SOD, CAT, IgM, AKP, LZM, ACP, complement C3 and complement C4 were determined. Real-time fluorescence quantitative PCR was used to measure gene expression in the liver, spleen, kidney, and intestinal tissues. On the 35th day, a challenge test was conducted to determine the immune protection rate of the vaccine. The results demonstrated that serum IgM antibody levels increased significantly in all vaccine groups after the initial immunization and continued to rise following the second booster immunization. Additionally, there was a notable increase in the levels of SOD, CAT, AKP, LZM, ACP, C3, and C4 in the serum after both immunizations, with peak values observed on Day 21. Real-time quantitative PCR revealed upregulation of IL-10, IL-1β, IFN-γ, and TNF-α expression after both immunizations, with the maximum levels occurring on the 21st day, followed by a decrease on the 28th day. This study investigated the effect of different vaccine concentrations on the immunological protection rate of C. auratus, aiming to provide a fundamental theoretical basis for double-vaccine preparation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.